AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 303 min read$BMY

Bristol Myers Squibb Q3 Earnings Call Highlights

Bristol Myers Squibb (BMY) reported Q3 earnings, with eight drugs generating over $1B annually. QVANTIG revenue rose 28% to $334M, while OPDIVO fell 6% to $2.4B. BREYANZI and CAMZYOS saw significant growth. The company highlighted FDA approvals and upcoming data for new treatments. BMY plans a $2.3B Houston manufacturing campus and remains active in business development.

Original reporting
finance.yahoo.com
Published Oct 30, 2026, 3:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 3:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bristol Myers Squibb Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BMYBullishMed
01

Why it matters

Provides fresh revenue numbers and FDA approval, indicating earnings beat potential.

02

Market read

BMY's strong Q3 results could lift broader pharma sector and influence investor sentiment.

03

What to watch

potential headwinds from competition and pricing pressure

Relevance 9/10Novelty 9/10Timing: post-earnings today

Background

BMY Q3 earnings call highlights product revenue and pipeline updates.

Company-level read

Ticker impact

$BMYBullishMedium confidence
Context

Q3 product revenues reported, e.g., Opdivo $2.4B, Breyanzi $526M, and FDA accelerated approval of Zenbexus.

Expected impact

likely modest upside as revenue growth exceeds expectations

Evidence & confidence

new revenue figures and approval suggest earnings beat and future sales momentum

Market effects

Sector

boosts biotech sector confidence

Regional

supports US pharma stocks

Global

reinforces global oncology pipeline optimism

Counterpoint

What could challenge this read

growth may be unsustainable if pipeline delays occur

Key entities

  • company
    Bristol Myers Squibb

    US-listed biopharma reporting Q3 results.

  • executive
    Chris Boerner

    CEO of Bristol Myers Squibb, presented earnings highlights.

Read at source← All news

StoryBristol‑Myers Squibb reports Q3 2026 results, lifts revenue outlook, trims FY26 EPS guidance

Also covered by

5 outlets

Related articles

OCT 29
$AMGNMedAI 8/10

Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data

At ESMO 2026, Amgen's tarlatamab (Imdelltra) with AstraZeneca's durvalumab (Imfinzi) showed improved survival in lung cancer. Genentech's divarasib outperformed Amgen's sotorasib (Lumakras) and Bristol Myers Squibb's adagrasib (Krazati) in KRAS G12C-mutated NSCLC. AstraZeneca's osimertinib (Tagrisso) plus savolitinib (Orpathys) and Merck's sacituzumab tirumotecan (Kelun-Biotech) also showed promising results.

pharmacytimes.com7 min
OCT 29
$BMYMedAI 8/10

Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Bristol Myers Squibb (BMY) reported Q3 revenue of $13.1B, up 7%, with its Growth Portfolio contributing $7.7B, up 12%. EPS was $1.05 GAAP and $1.35 adjusted, down 17%. The company raised 2026 revenue guidance to $49.75B-$50.25B. Growth was driven by multiple drugs, not just one. The earnings decline is due to acquisition-related costs, not weaker core business.

finance.yahoo.com2 min
OCT 29
$BMYMedAI 8/10

Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript

Bristol-Myers Squibb (BMY) reported Q3 2026 earnings with 12% growth in its portfolio, driven by key brands like Reblozyl and Camzyos. The company raised full-year guidance and highlighted regulatory approvals, including Symvexis for multiple myeloma. Pipeline advancements and manufacturing investments were also discussed, with several key readouts expected by year-end and into 2027.

finance.yahoo.com2 min
OCT 29
$BMYMed

Four Major Idiopathic Pulmonary Fibrosis Advances From 2026

In 2026, several advancements in idiopathic pulmonary fibrosis (IPF) therapies were reported. Endeavor BioMedicines' taladegib showed positive results in a phase 2a trial, increasing lung volume. Rein Therapeutics' LTI-03 received FDA Fast Track designation. United Therapeutics' Tyvaso sNDA was accepted, with positive phase 3 trial data. Bristol Myers Squibb's admilparant met primary endpoints in a phase 3 trial, showing improved lung function.

ajmc.com7 min
OCT 29
$LLYMed

Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue

Three major US drugmakers—Eli Lilly, Merck, and Bristol Myers Squibb—reported record quarterly revenue and raised annual forecasts, citing strong demand for treatments. Despite Trump's pricing pressure, shares rose significantly. The companies expect volume growth to offset any price reductions. The White House highlighted savings programs as accomplishments.

finance.yahoo.com2 min